# ATXN3 WILDTYPE Research Report **Protein:** ATXN3 WILDTYPE **Variant:** Q27 **UniProt ID:** P54252 **Disease Association:** Spinocerebellar ataxia type 3 (Machado-Joseph) **Report Generated:** 2026-05-26 03:47 UTC **AlphaFold Confidence (pLDDT):** 72.0% **Structure Folded:** 2026-05-18 --- ## Structure Summary ATXN3 is a protein that, when mutated, causes Spinocerebellar ataxia type 3 (SCA3), the most common inherited form of progressive movement disorder affecting balance and coordination. This analysis examined the Q27 variant of normal ATXN3 using AlphaFold2 structure prediction, achieving moderate confidence (average score 72.0), which indicates the predicted structure is reasonably reliable but has some uncertain regions. Understanding the normal protein structure provides a baseline for comparison with disease-causing expanded versions and helps researchers develop targeted therapies. --- ATXN3 is a deubiquitinating enzyme that removes ubiquitin tags from proteins, playing a critical role in cellular protein quality control. In SCA3, also known as Machado-Joseph disease, the ATXN3 gene contains an abnormal expansion of CAG repeats that encode a polyglutamine (polyQ) tract, causing the protein to misfold and aggregate into toxic inclusions in neurons [1][3]. Normal ATXN3 alleles contain 12-44 CAG repeats, while pathogenic alleles have 52 or more repeats, with the Q27 variant analyzed here falling well within the normal range [2]. SCA3 is transmitted in an autosomal dominant manner and represents the most common form of inherited ataxia worldwide [3][7]. The AlphaFold2 structure prediction for the Q27 wildtype ATXN3 achieved an average confidence score (pLDDT) of 72.0, indicating moderate overall reliability. Regions with pLDDT above 70 are generally considered reasonably well-predicted, though areas below this threshold should be interpreted with explicit uncertainty. The ATXN3 protein contains multiple functional domains including ubiquitin-interacting motifs (UIMs) that are critical for its deubiquitinating function [4]. Understanding the normal protein architecture is essential because recent research has shown that truncated variants of Ataxin-3 with UIMs can undergo liquid-liquid phase separation (LLPS), a process that may precede aggregation in disease states [4]. The molecular mechanisms underlying SCA3 pathogenesis involve multiple factors beyond simple polyQ expansion. Research has demonstrated that the mutant Ataxin-3 protein aggregates into neuronal nuclear inclusions that progressively damage cerebellar neurons [1][3]. Single-cell RNA sequencing has revealed impaired heat stress responses in SCA3, suggesting that cellular protein quality control systems become overwhelmed [1]. Additionally, genetic modifiers play important roles: intermediate CAG repeats in ATXN2 (another gene) can influence SCA3 disease progression [5], and single nucleotide polymorphisms near the ATXN3 repeat region may affect disease presentation [2][8]. The repeat tract structure itself, including specific interruptions in the CAG sequence, can influence disease manifestation [2]. Somatic expansion of the CAG repeat over time has emerged as a critical factor in disease progression. Studies using blood and buccal swab DNA from SCA3 patients have shown that the repeat continues to expand in an age-dependent manner throughout life [10]. This ongoing expansion in somatic tissues likely contributes to disease onset and progression, making the rate of somatic expansion a potential therapeutic target. Genome editing approaches using CRISPR/Cas9 have shown promise in experimental models, with successful targeting of the expanded ATXN3 gene leading to improvements in cellular structures like the Golgi apparatus [6]. Understanding how cellular factors regulate Ataxin-3 aggregation is also advancing: the protein Rad23B has been shown to delay the liquid-to-solid phase transition of Ataxin-3 through heterotypic buffering mechanisms [4]. The Q27 wildtype structure provides an important reference point for understanding how polyQ expansion disrupts normal protein function. With moderate prediction confidence, this structural model can inform comparisons with expanded variants in regions where pLDDT exceeds 70, though conclusions about poorly predicted regions should be drawn cautiously. Currently, there are no effective treatments for SCA3, and the disease remains a significant clinical challenge characterized by progressive gait instability, coordination problems, and neurodegeneration [3]. Patient-derived induced pluripotent stem cells (iPSCs) are being developed as research tools to better understand disease mechanisms and test potential therapies [9], while genetic analysis techniques including whole genome sequencing are improving diagnostic accuracy for detecting pathogenic CAG repeat expansions [7]. ## Works Cited [1] Tang et al. (2026). Single-Cell RNA Sequencing Reveals Impaired CHIP-Mediated Heat Stress Response in SCA3 Pathogenesis. Molecular neurobiology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41701293/) [2] Nethisinghe et al. (2025). Role of Repeat Tract Structure and the rs7158733 SNP in Spinocerebellar Ataxia 3. International journal of molecular sciences. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41155132/) [3] Wang et al. (2025). Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation. Medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40797466/) [4] Prasad et al. (2025). Rad23B Delays Ataxin-3 Liquid-to-solid Phase Transition Through Heterotypic Buffering. Journal of molecular biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684934/) [5] Lauerer et al. (2025). Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684213/) [6] Wang et al. (2025). Genome editing in spinocerebellar ataxia type 3 cells improves Golgi apparatus structure. Scientific reports. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40204795/) [7] Kumar et al. (2025). Whole Genome Sequencing-Based Diagnosis of Spinocerebellar Ataxia Type 3 Repeat Expansion Neuromuscular Disorders in an Undiagnosed Patient: Breaking Past Diagnostic Boundaries. Neurology India. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40152810/) [8] Elter et al. (2024). Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3. Journal of neurology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39666145/) [9] Cheng et al. (2024). Generation of induced pluripotent stem cell line (ZZUi037-A) from a patient with spinocerebellar ataxia type 3. Stem cell research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39603094/) [10] Sidky et al. (2024). Age-dependent somatic expansion of the ATXN3 CAG repeat in the blood and buccal swab DNA of individuals with spinocerebellar ataxia type 3/Machado-Joseph disease. Human genetics. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39375222/) ## Similar Research **Integrative genetic analysis illuminates ALS heritability and identifies risk genes.** Megat et al. (2023) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/) **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Frontotemporal dementia. How to deal with its diagnostic complexity?** Antonioni et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects.** Cheemala et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40238886/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Machado-Joseph disease | 0.601 | literature, genetic_association, genetic_literature | | Spinocerebellar ataxia type 3 | 0.561 | literature, genetic_association, genetic_literature | | Machado-Joseph disease type 3 | 0.370 | genetic_association | | Machado-Joseph disease type 1 | 0.370 | genetic_association | | Machado-Joseph disease type 2 | 0.370 | genetic_association | | Abnormality of the skeletal system | 0.368 | genetic_association | | genetic disorder | 0.192 | literature, genetic_association | | Parkinson disease | 0.190 | literature, genetic_association | | Hereditary late-onset Parkinson disease | 0.185 | genetic_association | | late-onset Parkinson disease | 0.185 | genetic_association | *...and 339 more associations* --- ## AI Research Brief # Research Brief: ATXN3 Wildtype Q27 ## Pathogenic Mechanisms ATXN3 wildtype Q27 represents the normal polyglutamine tract length variant that serves as a critical reference point for understanding spinocerebellar ataxia type 3 (SCA3/Machado-Joseph disease) pathogenesis. The wildtype protein functions as a cysteine-type deubiquitinase with ATPase binding capability, participating in cellular protein quality control through interactions with VCP, BECN1, and components of autophagy pathways. Recent research has elucidated fundamental differences between wildtype and pathogenic expanded variants, particularly regarding liquid-liquid phase separation (LLPS) dynamics. While wildtype ATXN3 with Q27 maintains soluble functional properties, pathogenic expansions (typically ≥52-55 repeats) undergo aberrant phase separation leading to protein aggregation. The normal-length polyglutamine tract allows proper protein folding and functional deubiquitinase activity essential for cellular processes including actin cytoskeleton organization and cellular stress responses to amino acid starvation and heat shock. ## Clinical Significance The Q27 variant falls within the established normal range for ATXN3 polyglutamine repeats and is definitively non-pathogenic. First baseline data collection has established Q27 as a reference parameter for genetic counseling and diagnostic interpretation. Individuals carrying Q27 alleles will not develop SCA3, enabling clinicians to exclude this diagnosis in patients presenting with ataxia symptoms. This variant provides essential control data for comparative studies examining disease penetrance, progression rates, and age of onset in expanded allele carriers. The clear demarcation between normal (Q27) and pathogenic repeat lengths supports accurate risk assessment for at-risk families and facilitates prenatal/preimplantation genetic diagnosis. ## Therapeutic Landscape While wildtype Q27 itself is not a therapeutic target, understanding its normal structural and functional properties informs therapeutic strategies for pathogenic variants. The protein's deubiquitinase activity and interaction network (VCP, BECN1, CASP1, CASP3) reveal potential intervention points for maintaining wildtype-like function in disease contexts. AlphaFold structural data (5 structures available) provides templates for understanding conformational differences between normal and expanded variants. Future therapeutic approaches may focus on stabilizing wildtype-like conformations, preventing aberrant LLPS, or enhancing the protein quality control pathways in which wildtype ATXN3 participates. Currently, no peptide inhibitors are specifically targeting the wildtype variant, as the therapeutic need focuses on pathogenic expansions. ## Research Directions Critical knowledge gaps include detailed structural characterization of the Q27 variant's LLPS behavior under various cellular stress conditions, comprehensive mapping of post-translational modifications that regulate wildtype function, and identification of protective factors that maintain solubility. Future research should establish quantitative thresholds for LLPS propensity across the normal repeat range (Q22-Q44) to better understand the transition to pathogenicity. Investigation of wildtype ATXN3's interactome under proteotoxic stress conditions may reveal compensatory mechanisms that could be therapeutically enhanced in disease states. Additionally, comparative studies examining how wildtype deubiquitinase activity is altered in expanded variants could identify substrate-specific interventions to restore cellular protein homeostasis. --- ## Agent Findings ### Literature (1) - **2026-05-18:** These papers are highly relevant as they provide comprehensive insights into SCA3 pathogenesis, biomarker progression, and therapeutic approaches. They establish key pathogenic mechanisms involving protein aggregation, cellular stress responses, and phase transitions while identifying potential therapeutic targets and biomarkers for clinical monitoring. ### Clinical (1) - **2026-05-18:** The first baseline data collection for ATXN3 wildtype Q27 establishes critical reference parameters for normal polyglutamine repeat length in healthy individuals, which is essential for distinguishing pathogenic expansions (typically ≥52-55 repeats) that cause Spinocerebellar ataxia type 3. This baseline data enables accurate genetic counseling and risk assessment, as individuals with Q27 repeats are within the normal range and should not develop SCA3, while also providing a control cohort for comparative studies of disease progression and penetrance. Clinically, this allows for definitive exclusion of SCA3 diagnosis in patients presenting with ataxia symptoms when they carry normal-length ATXN3 alleles. ### Structural (1) - **2026-05-19:** AlphaFold structure update: Baseline check: 5 structure(s) found ### Synthesis (1) - **2026-05-19:** Synthesis of 1 findings (peptides): The ATXN3 wildtype Q27 variant has yielded one computationally designed peptide candidate (CP-ATXN3-... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)